{"id":233085,"date":"2025-09-17T05:43:11","date_gmt":"2025-09-17T05:43:11","guid":{"rendered":"https:\/\/www.europesays.com\/us\/233085\/"},"modified":"2025-09-17T05:43:11","modified_gmt":"2025-09-17T05:43:11","slug":"3-small-cap-stocks-that-concern-us","status":"publish","type":"post","link":"https:\/\/www.europesays.com\/us\/233085\/","title":{"rendered":"3 Small-Cap Stocks That Concern Us"},"content":{"rendered":"

\"MYGN<\/p>\n

Many small-cap stocks have limited Wall Street coverage, giving savvy investors the chance to act before everyone else catches on.
\nBut the flip side is that these businesses have increased downside risk because they lack the scale and staying power of their larger competitors. <\/p>\n

Luckily for you, our mission at StockStory is to help you make money and avoid losses by sorting the winners from the losers. That said, here are three small-cap stocks to swipe left on and some alternatives you should look into instead. <\/p>\n

Myriad Genetics (MYGN)<\/p>\n

Market Cap: $697.8 million<\/p>\n

Founded in 1991 as one of the pioneers in translating genetic discoveries into clinical applications, Myriad Genetics (NASDAQ: MYGN<\/a>) develops genetic tests that assess disease risk, guide treatment decisions, and provide insights across oncology, women’s health, and mental health.<\/p>\n

Why Should You Dump MYGN?<\/strong><\/p>\n

    \n
  1. Muted 5.5% annual revenue growth over the last five years shows its demand lagged behind its healthcare peers<\/li>\n
  2. Negative returns on capital show management lost money while trying to expand the business, and its decreasing returns suggest its historical profit centers are aging<\/li>\n
  3. Diminishing returns on capital from an already low starting point show that neither management\u2019s prior nor current bets are going as planned<\/li>\n<\/ol>\n

    Myriad Genetics\u2019s stock price of $7.65 implies a valuation ratio of 85.9x forward P\/E. Read our free research report to see why you should think twice about including MYGN in your portfolio<\/a>. <\/p>\n

    PAR Technology (PAR)<\/p>\n

    Market Cap: $1.72 billion<\/p>\n

    Originally founded in 1968 as a defense contractor for the U.S. government, PAR Technology (NYSE: PAR<\/a>) provides cloud-based software, payment processing, and hardware solutions that help restaurants manage everything from point-of-sale to customer loyalty programs.<\/p>\n

    Why Does PAR Give Us Pause?<\/strong><\/p>\n

      \n
    1. Cash-burning history makes us doubt the long-term viability of its business model<\/li>\n
    2. Negative returns on capital show that some of its growth strategies have backfired<\/li>\n
    3. Short cash runway increases the probability of a capital raise that dilutes existing shareholders<\/li>\n<\/ol>\n

      At $43.84 per share, PAR Technology trades at 112.3x forward P\/E. Dive into our free research report to see why there are better opportunities than PAR<\/a>. <\/p>\n

      Affiliated Managers Group (AMG)<\/p>\n

      Market Cap: $6.67 billion<\/p>\n

      Using a partnership approach that preserves entrepreneurial culture at its portfolio companies, Affiliated Managers Group (NYSE: AMG<\/a>) is an investment firm that acquires stakes in boutique asset management companies while allowing them to maintain operational independence.<\/p>\n

      Why Is AMG Not Exciting?<\/strong><\/p>\n

        \n
      1. Flat sales over the last five years suggest it must find different ways to grow during this cycle<\/li>\n
      2. Earnings per share lagged its peers over the last two years as they only grew by 4.4% annually<\/li>\n<\/ol>\n

        Affiliated Managers Group is trading at $234.78 per share, or 9.4x forward P\/E. If you\u2019re considering AMG for your portfolio, see our FREE research report to learn more<\/a>. <\/p>\n

        High-Quality Stocks for All Market Conditions<\/p>\n

        Donald Trump\u2019s April 2025 “Liberation Day” tariffs sent markets into a tailspin, but stocks have since rebounded strongly, proving that knee-jerk reactions often create the best buying opportunities. <\/p>\n

        The smart money is already positioning for the next leg up. Don\u2019t miss out on the recovery – check out our Top 5 Growth Stocks for this month<\/a>. This is a curated list of our High Quality stocks that have generated a market-beating return of 183% over the last five years (as of March 31st 2025). <\/p>\n

        Stocks that made our list in 2020 include now familiar names such as Nvidia (+1,545% between March 2020 and March 2025) as well as under-the-radar businesses like the once-small-cap company Comfort Systems (+782% five-year return). Find your next big winner with StockStory today for free<\/a>. Find your next big winner with StockStory today<\/a>. Find your next big winner with StockStory today<\/a><\/p>\n

        StockStory is growing and hiring equity analyst and marketing roles. Are you a 0 to 1 builder passionate about the markets and AI? See the open roles here.<\/a><\/p>\n

        <\/p>\n","protected":false},"excerpt":{"rendered":"Many small-cap stocks have limited Wall Street coverage, giving savvy investors the chance to act before everyone else…\n","protected":false},"author":3,"featured_media":233086,"comment_status":"","ping_status":"","sticky":false,"template":"","format":"standard","meta":{"footnotes":""},"categories":[26],"tags":[815,159,67,132,68],"class_list":{"0":"post-233085","1":"post","2":"type-post","3":"status-publish","4":"format-standard","5":"has-post-thumbnail","7":"category-genetics","8":"tag-genetics","9":"tag-science","10":"tag-united-states","11":"tag-unitedstates","12":"tag-us"},"share_on_mastodon":{"url":"https:\/\/pubeurope.com\/@us\/115218048956344634","error":""},"_links":{"self":[{"href":"https:\/\/www.europesays.com\/us\/wp-json\/wp\/v2\/posts\/233085","targetHints":{"allow":["GET"]}}],"collection":[{"href":"https:\/\/www.europesays.com\/us\/wp-json\/wp\/v2\/posts"}],"about":[{"href":"https:\/\/www.europesays.com\/us\/wp-json\/wp\/v2\/types\/post"}],"author":[{"embeddable":true,"href":"https:\/\/www.europesays.com\/us\/wp-json\/wp\/v2\/users\/3"}],"replies":[{"embeddable":true,"href":"https:\/\/www.europesays.com\/us\/wp-json\/wp\/v2\/comments?post=233085"}],"version-history":[{"count":0,"href":"https:\/\/www.europesays.com\/us\/wp-json\/wp\/v2\/posts\/233085\/revisions"}],"wp:featuredmedia":[{"embeddable":true,"href":"https:\/\/www.europesays.com\/us\/wp-json\/wp\/v2\/media\/233086"}],"wp:attachment":[{"href":"https:\/\/www.europesays.com\/us\/wp-json\/wp\/v2\/media?parent=233085"}],"wp:term":[{"taxonomy":"category","embeddable":true,"href":"https:\/\/www.europesays.com\/us\/wp-json\/wp\/v2\/categories?post=233085"},{"taxonomy":"post_tag","embeddable":true,"href":"https:\/\/www.europesays.com\/us\/wp-json\/wp\/v2\/tags?post=233085"}],"curies":[{"name":"wp","href":"https:\/\/api.w.org\/{rel}","templated":true}]}}